TrialBritish journal of clinical pharmacology2026

Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study.

Xiaoying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.